Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Loss of IGF2 Imprinting: A Potential Marker of Colorectal Cancer Risk
Hengmi Cui,1*Marcia Cruz-Correa,1*Francis M. Giardiello,12David F. Hutcheon,1David R. Kafonek,1Sheri Brandenburg,1Yiqian Wu,1Xiaobing He,1Neil R. Powe,14Andrew P. Feinberg123
Loss of imprinting (LOI), an epigenetic alteration
affecting the insulin-like growth factor II gene (IGF2), is
found in normalcolonic mucosa of about 30% of colorectal cancer (CRC)
patients,but it is found in only 10% of healthy individuals. In a
pilotstudy to investigate the utility of LOI as a marker of CRC risk,we evaluated 172 patients at a colonoscopy clinic. The adjustedodds
ratio for LOI in lymphocytes was 5.15 for patients with apositive
family history [95% confidence interval (95% CI), 1.70to 16.96;
probability P = 0.002], 3.46 for patients with
adenomas(95% CI, 1.14 to 11.37; P = 0.026), and 21.7 for patients withCRC (95% CI, 3.48 to 153.6; P = 0.0005). LOI can be assayed witha DNA-based blood test, and it may be
a valuable predictive markerof an individual's risk for CRC.
1 Department of Medicine,
2 Department of Oncology,
3 Department of Molecular Biology and Genetics,
Johns Hopkins University School of Medicine, 1064 Ross Building, 720 Rutland Avenue, Baltimore, MD 21205, USA.
4 Department of Epidemiology, Johns Hopkins
Bloomberg School of Public Health, Baltimore, MD 21205, USA.
*
These authors contributed equally to this work.
To whom correspondence should be addressed. E-mail:
afeinberg{at}jhu.edu
The editors suggest the following Related Resources on Science sites:
In Science Magazine
PERSPECTIVES
David F. Ransohoff (14 March 2003) Science299 (5613), 1679.
[DOI: 10.1126/science.1083158] |Summary »|Full Text »|PDF »
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Intra-individual Change Over Time in DNA Methylation With Familial Clustering.
H. T. Bjornsson, M. I. Sigurdsson, M. D. Fallin, R. A. Irizarry, T. Aspelund, H. Cui, W. Yu, M. A. Rongione, T. J. Ekstrom, T. B. Harris, et al. (2008)
JAMA
299, 2877-2883
|Abstract »|Full Text »|PDF »
DNA Methyltransferase 1 and 3B Activate BAG-1 Expression via Recruitment of CTCFL/BORIS and Modulation of Promoter Histone Methylation.
L. Sun, L. Huang, P. Nguyen, K. S. Bisht, G. Bar-Sela, A. S. Ho, C. M. Bradbury, W. Yu, H. Cui, S. Lee, et al. (2008)
Cancer Res.
68, 2726-2735
|Abstract »|Full Text »|PDF »
Silent Assassin: Oncogenic Ras Directs Epigenetic Inactivation of Target Genes.
M. Esteller (2008)
N. Engl. J. Med.
358, 1148-1159
|Full Text »|PDF »
Is folic acid good for everyone?.
A D. Smith, Y.-I. Kim, and H. Refsum (2008)
Am. J. Clinical Nutrition
87, 517-533
|Abstract »|Full Text »|PDF »
Restriction Site-Specific Methylation Studies of Imprinted Genes with Quantitative Real-Time PCR.
S. Bruce, K. Hannula-Jouppi, C. M. Lindgren, M. Lipsanen-Nyman, and J. Kere (2008)
Clin. Chem.
54, 491-499
|Abstract »|Full Text »|PDF »
Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk.
A. Kaneda, C. J. Wang, R. Cheong, W. Timp, P. Onyango, B. Wen, C. A. Iacobuzio-Donahue, R. Ohlsson, R. Andraos, M. A. Pearson, et al. (2007)
PNAS
104, 20926-20931
|Abstract »|Full Text »|PDF »
Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing.
H. G. Linhart, H. Lin, Y. Yamada, E. Moran, E. J. Steine, S. Gokhale, G. Lo, E. Cantu, M. Ehrich, T. He, et al. (2007)
Genes & Dev.
21, 3110-3122
|Abstract »|Full Text »|PDF »
Examination of IGF2 and H19 Loss of Imprinting in Bladder Cancer.
H.-M. Byun, H.-L. Wong, E. A. Birnstein, E. M. Wolff, G. Liang, and A. S. Yang (2007)
Cancer Res.
67, 10753-10758
|Abstract »|Full Text »|PDF »
IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor.
E. K. Rowinsky, H. Youssoufian, J. R. Tonra, P. Solomon, D. Burtrum, and D. L. Ludwig (2007)
Clin. Cancer Res.
13, 5549s-5555s
|Abstract »|Full Text »|PDF »
Epigenetic modulation and cancer: effect of metabolic syndrome?.
Circulating Insulin-Like Growth Factor Binding Protein-1 and the Risk of Pancreatic Cancer.
B. M. Wolpin, D. S. Michaud, E. L. Giovannucci, E. S. Schernhammer, M. J. Stampfer, J. E. Manson, B. B. Cochrane, T. E. Rohan, J. Ma, M. N. Pollak, et al. (2007)
Cancer Res.
67, 7923-7928
|Abstract »|Full Text »|PDF »
A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.
Q.-s. Ji, M. J. Mulvihill, M. Rosenfeld-Franklin, A. Cooke, L. Feng, G. Mak, M. O'Connor, Y. Yao, C. Pirritt, E. Buck, et al. (2007)
Mol. Cancer Ther.
6, 2158-2167
|Abstract »|Full Text »|PDF »
Priorities in Colorectal Cancer Research: Recommendations From the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups.
P. J. O'Dwyer, S. G. Eckhardt, D. G. Haller, J. Tepper, D. Ahnen, S. Hamilton, A. B. Benson III, M. Rothenberg, N. Petrelli, H.-J. Lenz, et al. (2007)
J. Clin. Oncol.
25, 2313-2321
|Abstract »|Full Text »|PDF »
Up-regulation of DLK1 as an imprinted gene could contribute to human hepatocellular carcinoma.
J. Huang, X. Zhang, M. Zhang, J.-D. Zhu, Y.-L. Zhang, Y. Lin, K.-S. Wang, X.-F. Qi, Q. Zhang, G.-Z. Liu, et al. (2007)
Carcinogenesis
28, 1094-1103
|Abstract »|Full Text »|PDF »
Perspectives: The Possible Influence of Assisted Reproductive Technologies on Transgenerational Reproductive Effects of Environmental Endocrine Disruptors.
T. M. Price, S. K. Murphy, and E. V. Younglai (2007)
Toxicol. Sci.
96, 218-226
|Abstract »|Full Text »|PDF »
Heritable rather than age-related environmental and stochastic factors dominate variation in DNA methylation of the human IGF2/H19 locus.
B. T. Heijmans, D. Kremer, E. W. Tobi, D. I. Boomsma, and P. E. Slagboom (2007)
Hum. Mol. Genet.
16, 547-554
|Abstract »|Full Text »|PDF »
Epigenetics and cancer: towards an evaluation of the impact of environmental and dietary factors.
Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma.
L. Soroceanu, S. Kharbanda, R. Chen, R. H. Soriano, K. Aldape, A. Misra, J. Zha, W. F. Forrest, J. M. Nigro, Z. Modrusan, et al. (2007)
PNAS
104, 3466-3471
|Abstract »|Full Text »|PDF »
The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights.
A. A. Samani, S. Yakar, D. LeRoith, and P. Brodt (2007)
Endocr. Rev.
28, 20-47
|Abstract »|Full Text »|PDF »
Functional evaluation of novel soluble insulin-like growth factor (IGF)-II-specific ligand traps based on modified domain 11 of the human IGF2 receptor.
S. N. Prince, E. J. Foulstone, O. J. Zaccheo, C. Williams, and A. B. Hassan (2007)
Mol. Cancer Ther.
6, 607-617
|Abstract »|Full Text »|PDF »
Chimeric DNA methyltransferases target DNA methylation to specific DNA sequences and repress expression of target genes.
F. Li, M. Papworth, M. Minczuk, C. Rohde, Y. Zhang, S. Ragozin, and A. Jeltsch (2007)
Nucleic Acids Res.
35, 100-112
|Abstract »|Full Text »|PDF »
Heredity and DNA methylation in colorectal cancer.
Colorectal cancer: a model for epigenetic tumorigenesis.
J J L Wong, N J Hawkins, and R L Ward (2007)
Gut
56, 140-148
|Full Text »|PDF »
The cancer epigenome--components and functional correlates.
A. H. Ting, K. M. McGarvey, and S. B. Baylin (2006)
Genes & Dev.
20, 3215-3231
|Abstract »|Full Text »|PDF »
MMASS: an optimized array-based method for assessing CpG island methylation.
A. E. K. Ibrahim, N. P. Thorne, K. Baird, N. L. Barbosa-Morais, S. Tavare, V. P. Collins, A. H. Wyllie, M. J. Arends, and J. D. Brenton (2006)
Nucleic Acids Res.
34, e136
|Abstract »|Full Text »|PDF »
Gain of allelic gene expression for IGF-II occurs frequently in Barrett's esophagus.
L. A. Feagins, N. Susnow, H. Y. Zhang, S. Pearson, C. Owen, W. F. Schmalstieg, L. S. Terada, S. J. Spechler, R. D. Ramirez, and R. F. Souza (2006)
Am J Physiol Gastrointest Liver Physiol
290, G871-G875
|Abstract »|Full Text »|PDF »
Suppression of Intestinal Neoplasia by Deletion of Dnmt3b.
H. Lin, Y. Yamada, S. Nguyen, H. Linhart, L. Jackson-Grusby, A. Meissner, K. Meletis, G. Lo, and R. Jaenisch (2006)
Mol. Cell. Biol.
26, 2976-2983
|Abstract »|Full Text »|PDF »
Imprinting of IGF2 P0 transcript and novel alternatively spliced INS-IGF2 isoforms show differences between mouse and human.
D. Monk, R. Sanches, P. Arnaud, S. Apostolidou, F.A. Hills, S. Abu-Amero, A. Murrell, H. Friess, W. Reik, P. Stanier, et al. (2006)
Hum. Mol. Genet.
15, 1259-1269
|Abstract »|Full Text »|PDF »
Frequent IGF2/H19 Domain Epigenetic Alterations and Elevated IGF2 Expression in Epithelial Ovarian Cancer.
S. K. Murphy, Z. Huang, Y. Wen, M. A. Spillman, R. S. Whitaker, L. R. Simel, T. D. Nichols, J. R. Marks, and A. Berchuck (2006)
Mol. Cancer Res.
4, 283-292
|Abstract »|Full Text »|PDF »
Post-weaning diet affects genomic imprinting at the insulin-like growth factor 2 (Igf2) locus.
R. A. Waterland, J.-R. Lin, C. A. Smith, and R. L. Jirtle (2006)
Hum. Mol. Genet.
15, 705-716
|Abstract »|Full Text »|PDF »
High-throughput DNA methylation profiling using universal bead arrays.
M. Bibikova, Z. Lin, L. Zhou, E. Chudin, E. W. Garcia, B. Wu, D. Doucet, N. J. Thomas, Y. Wang, E. Vollmer, et al. (2006)
Genome Res.
16, 383-393
|Abstract »|Full Text »|PDF »
Soluble IGF2 Receptor Rescues ApcMin/+ Intestinal Adenoma Progression Induced by Igf2 Loss of Imprinting.
J. Harper, J. L. Burns, E. J. Foulstone, M. Pignatelli, S. Zaina, and A. B. Hassan (2006)
Cancer Res.
66, 1940-1948
|Abstract »|Full Text »|PDF »
The Relationship of Insulin-Like Growth Factor-II, Insulin-Like Growth Factor Binding Protein-3, and Estrogen Receptor-{alpha} Expression to Disease Progression in Epithelial Ovarian Cancer.
L. Lu, D. Katsaros, A. Wiley, I. A. Rigault de la Longrais, H. A. Risch, M. Puopolo, and H. Yu (2006)
Clin. Cancer Res.
12, 1208-1214
|Abstract »|Full Text »|PDF »
Multiplexed profiling of candidate genes for CpG island methylation status using a flexible PCR/LDR/Universal Array assay.
Y.-W. Cheng, C. Shawber, D. Notterman, P. Paty, and F. Barany (2006)
Genome Res.
16, 282-289
|Abstract »|Full Text »|PDF »
Risk Stratification of Colon Carcinogenesis through Enhanced Backscattering Spectroscopy Analysis of the Uninvolved Colonic Mucosa.
H. K. Roy, Y. L. Kim, Y. Liu, R. K. Wali, M. J. Goldberg, V. Turzhitsky, J. Horwitz, and V. Backman (2006)
Clin. Cancer Res.
12, 961-968
|Abstract »|Full Text »|PDF »
Loss of Imprinting of IGF2: A Common Epigenetic Modifier of Intestinal Tumor Risk.
Positive Correlation of Insulin-Like Growth Factor-II with Proliferating Cell Index in Patients with Colorectal Neoplasia.
R. Zhao, M. Berho, J. Nogueras, D. Sands, E. Weiss, S. Wexner, F. M. Giardiello, and M. Cruz-Correa (2005)
Cancer Epidemiol. Biomarkers Prev.
14, 1819-1822
|Abstract »|Full Text »|PDF »
Diagnostic and Therapeutic Applications of Epigenetics.
Loss of Imprinting of Igf2 Alters Intestinal Maturation and Tumorigenesis in Mice.
T. Sakatani, A. Kaneda, C. A. Iacobuzio-Donahue, M. G. Carter, S. de Boom Witzel, H. Okano, M. S. H. Ko, R. Ohlsson, D. L. Longo, and A. P. Feinberg (2005)
Science
307, 1976-1978
|Abstract »|Full Text »|PDF »
The Insulin-Like Growth Factor-II Receptor Gene Is Associated with Type 1 Diabetes: Evidence of a Maternal Effect.
J. A. McCann, Y. Q. Xu, R. Frechette, L. Guazzarotti, and C. Polychronakos (2004)
J. Clin. Endocrinol. Metab.
89, 5700-5706
|Abstract »|Full Text »|PDF »
Cis-Acting Regulatory Variation in the Human Genome.
Z. Kemp, C. Thirlwell, O. Sieber, A. Silver, and I. Tomlinson (2004)
Hum. Mol. Genet.
13, R177-R185
|Abstract »|Full Text »|PDF »
A novel real-time PCR assay for quantitative analysis of methylated alleles (QAMA): analysis of the retinoblastoma locus.
M. Zeschnigk, S. Bohringer, E. A. Price, Z. Onadim, L. Masshofer, and D. R. Lohmann (2004)
Nucleic Acids Res.
32, e125
|Abstract »|Full Text »|PDF »
Use of DNA from Human Stools to Detect Aberrant CpG Island Methylation of Genes Implicated in Colorectal Cancer.
N. J. Belshaw, G. O. Elliott, E. A. Williams, D. M. Bradburn, S. J. Mills, J. C. Mathers, and I. T. Johnson (2004)
Cancer Epidemiol. Biomarkers Prev.
13, 1495-1501
|Abstract »|Full Text »|PDF »
Colorectal Adenomas: A Prototype for the Use of Surrogate End Points in the Development of Cancer Prevention Drugs.
G. J. Kelloff, R. L. Schilsky, D. S. Alberts, R. W. Day, K. Z. Guyton, H. L. Pearce, J. C. Peck, R. Phillips, and C. C. Sigman (2004)
Clin. Cancer Res.
10, 3908-3918
|Full Text »|PDF »
Limitations of the Odds Ratio in Gauging the Performance of a Diagnostic, Prognostic, or Screening Marker.
M. S. Pepe, H. Janes, G. Longton, W. Leisenring, and P. Newcomb (2004)
Am. J. Epidemiol.
159, 882-890
|Abstract »|Full Text »|PDF »
Loss of Insulin-Like Growth Factor-II Imprinting and the Presence of Screen-Detected Colorectal Adenomas in Women.
K. Woodson, A. Flood, L. Green, J. A. Tangrea, J. Hanson, B. Cash, A. Schatzkin, and P. Schoenfeld (2004)
J Natl Cancer Inst
96, 407-410
|Abstract »|Full Text »|PDF »
An association between variants in the IGF2 gene and Beckwith-Wiedemann syndrome: interaction between genotype and epigenotype.
A. Murrell, S. Heeson, W. N. Cooper, E. Douglas, S. Apostolidou, G. E. Moore, E. R. Maher, and W. Reik (2004)
Hum. Mol. Genet.
13, 247-255
|Abstract »|Full Text »|PDF »
Evolution of Imprinted Tumor Susceptibility Genes: RANDY L. JIRTLE, Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710.
CTCF Binding at the Insulin-Like Growth Factor-II (IGF2)/H19 Imprinting Control Region Is Insufficient to Regulate IGF2/H19 Expression in Human Tissues.
G. A. Ulaner, Y. Yang, J.-F. Hu, T. Li, T. H. Vu, and A. R. Hoffman (2003)
Endocrinology
144, 4420-4426
|Abstract »|Full Text »|PDF »
Can a Blood Test Detect Increased Risk for Colon Cancer?.
(2003)
Journal Watch (General)
2003, 4
|Full Text »